Ann: Trading Halt, page-15

Offer Price:

$0.004 per share

1-for-1 attaching option exercisable at $0.004 and will expire 8 months from issuance.

Each option will have a piggyback right, whereby if it is exercised within 5 months of issuance, a further option will be issued with an exercise price of $0.005 and further 8 month expiry from the date of issuance.

Discount:

• 50% to the Last Traded Price of $0.008
• 44% to the 15-day VWAP of $0.0072

Offer Details:

Placement to raise $4,000,000, comprising 1,000,000,000 Offer securities, to be allotted via 2 tranches (1/4 T1 + 3/4 T2) as follows:

• Tranche 1 – 164.3m shares (~$0.66m), subject to the Company’s placement capacity under ASX LR 7.1; and
• Tranche 2 – 835.7m shares (~$3.34m), subject to shareholder approval to be sought at an EGM.

A cornerstone US-based family office has committed US$1.0m to the Placement (or ~A$1.6m), to settle in Tranche 2.

The Company and Joint Lead Managers reserve the right to accept oversubscriptions.

Use of Proceeds:

• CHM CDH17 trial ($3m),
• CORE-NK ($0.5m),
• working capital and costs of the Offer ($0.5m)

Investment Highlights:

CHM CDH17 (Program 1: CAR T)

• CAR-T for gastrointestinal cancers, including bowel cancer – LEAD PROGRAM
• Dose Level 1 completed; four patients dosed
• Excellent safety and early efficacy signals; no off- target effects. Stable disease in rapidly progressing patient observed at Dose level 1.
• Recruitment rate is exceptional with ten patients on waitlist. Ready to proceed to dose level 2

CHM CLTX (Program 2: CAR T)

• CAR-T for brain cancer
• Ongoing Phase 1B clinical trial in recurrent glioblastoma

CHM CORE-NK (Program 3: Natural Killer Cells)

• Positive Phase 1A clinical trial in colorectal cancer (CRC) and acute myeloid leukemia (AML)
• Two ongoing Phase 1B trials in AML
• In ADVENT-AML, 2 of 3 frontline patients achieved CRi (remission); 1 patient achieved Stable Disease
• First ever frontline AML trial globally to incorporate NK cell therapy

Proven Team

• Paul Hopper founded CHM and holds 10.8% – sold Viralytics to Merck for ~A$500m in 2018. Also founded ASX-listed companies ASX:RAD ASX:IMU
• Dr Rebecca McQualter (CEO) – formerly Novartis, Amgen & GSK. PhD in cell therapy & regenerative medicine

Near Term Catalysts & Imminent Newsflow

• CHM CDH17 – Phase 1/2 preliminary data – IMMINENT INTERIM CLINICAL TRIAL DATA – Dose level 2
• CHM CORE-NK – Phase 1B ADVENT AML Frontline preliminary data